Lactylation‐Driven IGF2BP3‐Mediated Serine Metabolism Reprogramming and RNA m6A—Modification Promotes Lenvatinib Resistance in HCC
Abstract Acquired resistance remains a bottleneck for molecular‐targeted therapy in advanced hepatocellular carcinoma (HCC). Metabolic adaptation and epigenetic remodeling are recognized as hallmarks of cancer that may contribute to acquired resistance. In various lenvatinib‐resistant models, increa...
Saved in:
| Main Authors: | Yuanxiang Lu, Jinghan Zhu, Yuxin Zhang, Wentao Li, Yixiao Xiong, Yunhui Fan, Yang Wu, Jianping Zhao, Changzhen Shang, Huifang Liang, Wanguang Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202401399 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma
by: Jinghan Zhu, et al.
Published: (2025-08-01) -
Lactylation‐Driven HECTD2 Limits the Response of Hepatocellular Carcinoma to Lenvatinib
by: Runyu Dong, et al.
Published: (2025-04-01) -
IGF1/IGF1R signaling promotes the expansion of liver CSCs and serves as a potential therapeutic target in HCC
by: Qiuju Tian, et al.
Published: (2025-06-01) -
IGF2BP2: an m6A reader that affects cellular function and disease progression
by: Siyi Liu, et al.
Published: (2025-04-01) -
Research progress of serine hydroxymethyltransferase inhibitors in tumor treatment
by: Yili CHEN, et al.
Published: (2025-02-01)